ESR introduction and
outline ESR Project 5
Born in Altamura, Italy, she obtained her bachelor’s degree in Biological Sciences at the University of Bari in 2016. Shortly thereafter, she moved to enroll in the Functional Genomics Master’s course at the University of Trieste.
During her studies, she developed an interest in gene therapy. She participated to the Erasmus+ Traineeship program and she joined the “Immunology and Liver Diseases” INSERM laboratory (French National Medical Research Institute). The hosting research center, Genethon (Evry, France) is a private non-profit institute focused on the development of gene therapies for rare inherited diseases. During her six months internship she worked on AAV gene therapy approaches addressed to the Glycogen Storage Disease type II (or Pompe Disease).
After she obtained her Master’s degree in 2018, she continued carrying out her projects at Genethon until February 2020. She worked on the optimization of different transgene expression cassettes in the context of AAV-mediated gene therapy targeting the liver. She addressed her work to glycogen storage diseases and Hemophilia B.
Curious to experiment the knowledge on omics sciences provided by her studies, Isabella started in april 2020 her PhD research studies at the King’s College of London, in the context of the H2020 TRAIN-HEART consortium. She is measuring the targetome and the interactome of new ncRNAs involved in the regulation of cardiac tissue remodeling during heart ischemia. She is integrating bioinformatics approaches, target-prediction algorithms and advanced cardiovascular proteomic analysis in different models to identify human homologues involved in the ischemic heart failure.
- University Medical Center Hamburg-Eppendorf (group of Prof. Eschenhagen, experimental pharmacology and toxicology)
-Miltenyi Biotec GmbH (group of Dr Eckardt, cardiac research)